II. Epidemiology
- Most common cause of Thyrotoxicosis in the United States (up to 60-80% of cases)
- Prevalence: 20 to 50 in 100,000
- Gender: More common in women
III. Pathophysiology
- Autoimmune disorder
- Thyroid stimulating antibodies bind TSH receptors, resulting in Thyroid Hormone synthesis and release
- Associated with Thyroid Gland hyperplasia and Goiter
IV. Risk Factors
- Female gender (RR 4 compared with males)
- Autoimmune Disorder
- Family History of Graves Disease (or other autoimmune disorder)
- Tobacco Abuse
- Iodine exposure
V. Findings
- See Hyperthyroidism
- Older patients may present less specifically (e.g. Fatigue, weight loss, Atrial Fibrillation)
VI. Signs: Specific to Grave's Disease
- See Hyperthyroidism
- Diffuse, smooth Goiter- Palpated thrill or audible bruit over Thyroid
 
- Infiltrative ophthalmopathy or orbitopathy (Thyroid Eye Disease)- Ophthalmoplegia
- Proptosis (Exophthalmos) in 25-50% of cases
- Periorbital swelling
 
- Dermopathy- Pretibial Myxedema (Thyroid dermopathy, 1.5% of cases)- Swelling over the tibia
- Peau d' orange skin changes
 
- Thyroid Acropachy- Hand soft tissue swelling and Digital Clubbing
 
- Skin Pigment Changes- Patchy Hyperpigmentation or vitilgo
 
 
- Pretibial Myxedema (Thyroid dermopathy, 1.5% of cases)
VII. Differential Diagnosis
- See Hyperthyroidism
VIII. Labs
- See Hyperthyroidism
- 
                          Thyroid Stimulating Immunoglobulin (TSH Receptor Antibody)- Test Sensitivity: 97%
- Test Specificity: >=98%
- Linked with ophthalmopathy
- May be used to monitor effects of treatment
- Usually not needed for diagnosis- However, may be used in lieu of Thyroid uptake scan in Grave's Disease diagnosis
 
 
- 
                          Antithyroid Peroxidase Antibody negative- Contrast with positive in Hashimoto's Thyroiditis
 
IX. Imaging
- 
                          Thyroid uptake and scan (first-line study)- Diffusely high Radioactive Iodine uptake
 
- Thyroid Ultrasound with doppler (if performed)- Thyroid hypervascularity with increased flow
 
X. Management
- See Hyperthyroidism Management
- Referral to ophthalmology for ocular involvement
- Antithyroid Medications (Thionamides)- Indications- Grave's Disease without Goiter- Thionamides are first-line treatment
- Result in euthyroid state within 18 months in up to 50%
 
 
- Grave's Disease without Goiter
- Medications- Methimazole 15-30 mg per day (up to 120 mg)
- Propylthiouracil (PTU) 100-200 mg orally every 8 hours- Indicated in pregnancy first trimester
 
 
- Monitoring- See Antithyroid Medications
- Thyroid function- First: T4 Free, Total T3 every 4-6 weeks until euthyroid
- Next: TSH, T4 Free every 3-6 months
 
- Adverse Effects- Agranulocytosis (CBC)
- Hepatotoxicity (LFT)
 
 
- Efficacy: Predictors of remission with Thionamides- TSH Receptor Antibody negative
- Non-smoker
- Female Gender
 
 
- Indications
- 
                          Radioactive Iodine (RAI)- Indications- Failed remission with Thionamides after 12-24 months
- High dose Thionamides required or adverse effects
- Toxic Multinodular Goiter
 
- Contraindications
- Efficacy- Effective in Graves Disease in >90% of patients
 
- Monitoring- Thyroid Function Tests every 4-6 weeks
- Anticipate Hypothyroidism in up to 86% of Graves Disease patients treated with RAI
 
- Precautions- RAI exacerbates Thyroid Eye Disease, esp. in smokers (pretreat with Corticosteroids)
 
 
- Indications
- 
                          Thyroidectomy- See Thyroidectomy for indications
 
